Evidence map›Paper›PMID 41974809›Full record

ArticleScientific reports2026

Integrated in silico and in vitro evaluation of Camellia sinensis phytosomes in estrogen receptor-positive breast cancer.

Kunal Bhattacharya, Meher Rijwana Afrin, Pankaj Ghritakousik Upadhyaya, Md Muzahidul Islam, Rituparna Kalita, Nongmaithem Randhoni Chanu, Pukar Khanal, Shriram D Ranade, Dibyajyoti Das, Satyendra Deka and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Kunal BhattacharyaCenter for Computational Drug Discovery, Pratiksha Institute of Pharmaceutical Sciences, Guwahati, 781026, Assam, India.
Meher Rijwana AfrinCenter for Computational Drug Discovery, Pratiksha Institute of Pharmaceutical Sciences, Guwahati, 781026, Assam, India.
Pankaj Ghritakousik UpadhyayaCenter for Computational Drug Discovery, Pratiksha Institute of Pharmaceutical Sciences, Guwahati, 781026, Assam, India.
Md Muzahidul IslamCenter for Computational Drug Discovery, Pratiksha Institute of Pharmaceutical Sciences, Guwahati, 781026, Assam, India.
Rituparna KalitaCenter for Computational Drug Discovery, Pratiksha Institute of Pharmaceutical Sciences, Guwahati, 781026, Assam, India.
Nongmaithem Randhoni ChanuDepartment of Pharmaceutics, Pratiksha Institute of Pharmaceutical Sciences, Guwahati, 781026, Assam, India.
Pukar KhanalSilicon Script Sciences Private Limited, Bharatpur, Ghorahi, Dang, 22400, Nepal.
Shriram D RanadeDepartment of Pharmaceutical Chemistry, Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education, Manipal, India. shriram.ranade@manipal.edu.
Dibyajyoti DasCenter for Computational Drug Discovery, Pratiksha Institute of Pharmaceutical Sciences, Guwahati, 781026, Assam, India.
Satyendra DekaCenter for Computational Drug Discovery, Pratiksha Institute of Pharmaceutical Sciences, Guwahati, 781026, Assam, India.
H Prem MeiteiCenter for Computational Drug Discovery, Pratiksha Institute of Pharmaceutical Sciences, Guwahati, 781026, Assam, India.
Abdul HashimCenter for Computational Drug Discovery, Pratiksha Institute of Pharmaceutical Sciences, Guwahati, 781026, Assam, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Endocrine therapy has improved outcomes in estrogen receptor-positive breast cancer (ERPBC), but resistance and relapse remain common. Camellia sinensis contains polyphenols with reported anticancer effects, but their key targets, systems-level mechanisms and optimised delivery for ERPBC are not well defined. Ethanolic leaf extract of Camellia sinensis was profiled by HR-LCMS/MS, and 11 abundant phytocompounds were taken forward for network pharmacology analysis against ERPBC targets. Hub genes and pathways were validated by molecular docking and 200 ns molecular dynamics simulations, focusing on Theacitrin C–CTNNB1 and Plathymenin–ESR1 complexes. A phospholipid phytosome of the extract was then formulated and characterised for particle size, zeta potential and morphology, followed by in vitro cytotoxicity on MCF-7 and L929 cells using the MTT assay. 36 overlapping targets and 8 hub genes were identified. Theacitrin C and Plathymenin showed strong, dynamically stable binding to CTNNB1 and ESR1. The phytosome exhibited a mean size of 519 nm, zeta potential of − 23.0 ± 1.1 mV and mainly spherical particles. It was highly biocompatible toward L929 cells (84.31% viability at 1000 µg/mL) and showed dose-dependent cytotoxicity in MCF-7 cells (IC₅₀ 445.55 µg/mL). Camellia sinensis-derived phytochemicals, particularly Theacitrin C and Plathymenin, appear to modulate CTNNB1- and ESR1-centred networks in ERPBC, and their phytosomal delivery offers a stable, selectively cytotoxic formulation. These findings justify further preclinical evaluation of Camellia sinensis phytosomes as multi-target adjuncts for ERPBC.

Indexed as

Breast NeoplasmsCamellia sinensisPhytosomesPlant ExtractsReceptors, EstrogenAnimalsbeta CateninCell Line, TumorComputer SimulationEstrogen Receptor alphaFemaleHumansMCF-7 CellsMiceMolecular Docking SimulationMolecular Dynamics Simulationbeta CateninESR1 protein, humanEstrogen Receptor alphaPhytosomesPlant ExtractsReceptors, EstrogenCamellia sinensisEstrogen receptor-positive breast cancerMCF-7 cellsMolecular dynamicsNetwork pharmacology

Identifiers

PMID41974809
PMCPMC13234134

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.